HKDC1: A Protein Implicated in Diseases (G80201)

Target Name: HKDC1

NCBI ID: G80201

HKDC1

HKDC1: A Protein Implicated in Diseases

HKDC1 (Hexokinase domain-containing protein 1) is a protein that is expressed in various cell types of the human body, including muscle, nerve, and heart cells. It is a member of the hexokinase enzyme family, which is a group of transmembrane proteins that play a crucial role in various cellular processes, including metabolism, signal transduction, and cellular signaling. HKDC1 is unique due to its ability to catalyze the hydrolysis of ATP to ADP, which is a key step in the energy metabolism of the cell.

Disease association

HKDC1 is strongly associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that HKDC1 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, HKDC1 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Furthermore, studies have also shown that HKDC1 is involved in the development and progression of cardiovascular diseases, such as heart failure and ischemia-reperfusion injury.

Drug targeting

HKDC1 has been identified as a potential drug target due to its unique structure and its involvement in various diseases. One approach to targeting HKDC1 is to use small molecules that can modulate its activity. For example, several studies have shown that inhibitors of the hexokinase enzyme can effectively inhibit the growth and survival of cancer cells that are expressing HKDC1. Additionally, studies have also shown that inhibitors of HKDC1 can effectively alleviate symptoms of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another approach to targeting HKDC1 is to use antibodies that can specifically bind to it. Studies have shown that antibodies specific for HKDC1 can effectively target the protein in cancer cells and neurodegenerative diseases, and can also inhibit its activity.

Biomarker

HKDC1 can also be used as a biomarker for various diseases. For example, studies have shown that HKDC1 levels are significantly increased in the brains of patients with Alzheimer's disease, and that these levels are also increased in the brains of patients with Parkinson's disease. Additionally , studies have also shown that HKDC1 levels are significantly increased in the hearts of patients with heart failure, and that these levels are also increased in the hearts of patients with ischemia-reperfusion injury. Therefore, HKDC1 can be used as a biomarker for various diseases , including cancer, neurodegenerative diseases, and cardiovascular diseases.

Conclusion

HKDC1 is a protein that is involved in various cellular processes in the human body. It is a member of the hexokinase enzyme family and is unique due to its ability to catalyze the hydrolysis of ATP to ADP.HKDC1 is strongly associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, it is a promising target for drug development. Additionally, HKDC1 can also be used as a biomarker for various diseases. Further studies are needed to fully understand the role of HKDC1 in diseases and to develop effective treatments.

Protein Name: Hexokinase Domain Containing 1

Functions: Catalyzes the phosphorylation of hexose to hexose 6-phosphate, although at very low level compared to other hexokinases (PubMed:30517626). Has low glucose phosphorylating activity compared to other hexokinases (PubMed:30517626). Involved in glucose homeostasis and hepatic lipid accumulation. Required to maintain whole-body glucose homeostasis during pregnancy; however additional evidences are required to confirm this role (By similarity)

The "HKDC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HKDC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets